Business Wire·Nov 11, 2026, 4:05 PM ET

Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update

ACOG

Alpha Cognition Inc. reported third quarter 2026 net product revenue of $7.8 million for ZUNVEYL, representing a 30% increase quarter-over-quarter and a 230% increase year-over-year.
Bottles dispensed rose 31% sequentially to 10,896 in Q3 2026, with cumulative prescriptions exceeding 30,000 since launch.
Cumulative prescribers reached 2,410, surpassing the original 2026 goal of 2,000 a quarter early, while sequential quarterly prescriber growth was 22% to 1,639.
CONVERGE real-world data showed 79.1% of ZUNVEYL residents new to AChEI therapy reached a therapeutic dose within 180 days, compared to 37.3% for generic AChEIs.
Operating expenses increased slightly to $13.7 million, resulting in an improved operating loss of $6.4 million for the quarter.
The company reported $37.8 million in cash and cash equivalents as of September 30, 2026, with no debt outstanding.
Medicare Part D contracts cover approximately 45 million lives, with a 95% approval rate for prescriptions where prior authorization support is provided.
Commercial productivity metrics showed a conversion rate from prescribers called on to prescribing professionals exceeding 50% in Q3 2026.
The company reiterated full-year 2026 R&D and SG&A expense guidance of $50 million to $54 million.
Net loss for the quarter was $7.6 million, or $0.35 per share, compared to a net income of $574 thousand in the same period in 2025.
Enrollment in the RESOLVE Phase 4 trial remains ongoing, with completion expected in Q2 2027.
A patent application covering the proprietary manufacturing process for benzgalantamine was published by the U.S. Patent and Trademark Office.
Alpha Cognition hosted a conference call and webcast on November 11, 2026, at 4:30 p.m. ET to discuss these results.